Etanercept for Wegener's Granulomatosis - Related Studies

Etanercept for Wegener's Granulomatosis

This study has been completed.

Study NCT00005007. Last updated on December 19, 2007. Information provided by National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Wegener's Granulomatosis

2	Additional conditions recognized in this trial
		Wegener Granulomatosis

3	More general conditions related to this trial
		Cardiovascular Diseases
		Kidney Diseases
		Lung Diseases
		Lung Diseases, Interstitial
		Respiratory Tract Diseases
		Urologic Diseases
		Vascular Diseases
		Vasculitis

4	Interventions listed in this trial
		Etanercept

5	Additional drug interventions recognized in this trial
		TNFR-Fc fusion protein

6	More general drug interventions related to this trial
		Analgesics
		Analgesics, Non-Narcotic
		Anti-Inflammatory Agents
		Anti-Inflammatory Agents, Non-Steroidal
		Antirheumatic Agents
		Central Nervous System Agents
		Gastrointestinal Agents
		Immunologic Factors
		Immunosuppressive Agents
		Peripheral Nervous System Agents
		Pharmacologic Actions
		Physiological Effects of Drugs
		Sensory System Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
		FDA Office of Orphan Products Development